ELI LILLY AND COMPANY

NYSE: LLY (Eli Lilly and Company)

Last update: 04 Oct, 1:51PM

883.80

-1.75 (-0.20%)

  • 1D -0.20%
  • 5D -3.91%
  • 1M -2.34%
  • 6M 18.48%
  • YTD 49.24%
  • 1Y 45.54%
  • 5Y 713.51%
Previous Close 885.55
Open 885.91
Volume 1,268,617
Avg. Volume (3M) 3,212,137
Market Cap 795,796,504,576
Price / Earnings (TTM) 108.44
Price / Earnings (Forward) 39.06
Price / Sales 20.60
Price / Book 58.90
52 Weeks Range
542.71 (-38%) — 972.53 (10%)
Earnings Date 30 Oct 2024
TTM Dividend Yield 0.57%
Profit Margin 18.86%
Operating Margin (TTM) 39.09%
Diluted EPS (TTM) 8.15
Quarterly Revenue Growth (YOY) 36.00%
Quarterly Earnings Growth (YOY) 68.30%
Total Debt/Equity (MRQ) 212.88%
Current Ratio (MRQ) 1.11
Operating Cash Flow (TTM) 4.51 B
Levered Free Cash Flow (TTM) -675.32 M
Return on Assets (TTM) 13.70%
Return on Equity (TTM) 59.25%

Market Trend

Short Term Medium Term
Industry Drug Manufacturers - General (US) Bullish Bullish
Drug Manufacturers - General (Global) Bullish Bullish
Stock Eli Lilly and Company Bearish Bullish

Stockmoo Score

1.5
Analyst Consensus 2.0
Insider Activity NA
Price Volatility 2.0
Technical Moving Averages 0.0
Technical Oscillators 2.0
Average 1.50

Similar Stocks

Stock Market Cap DY P/E P/B
LLY 796 B 0.57% 108.44 58.90
NVS 239 B 3.37% 23.96 5.64
JNJ 396 B 2.96% 27.19 5.53
ABBV 285 B 2.84% 48.13 49.63
MRK 278 B 2.81% 20.32 6.36
PFE 166 B 5.71% - 1.92

Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Sector Healthcare
Industry Drug Manufacturers - General
Investment Style Large Growth
% Held by Insiders 0.15%
% Held by Institutions 83.54%

Ownership

Name Date Shares Held
Lilly Endowment Inc 30 Jun 2024 97,367,369
52 Weeks Range
542.71 (-38%) — 972.53 (10%)
Price Target Range
885.00 (0%) — 1,125.00 (-99%)
High 1,125.00 (B of A Securities, 27.29%) Buy
Median 1,055.00 (19.37%)
Low 885.00 (Cantor Fitzgerald, 0.14%) Buy
Average 1,051.25 (18.95%)
Total 12 Buy
Avg. Price @ Call 913.61
Firm Date Target Price Call Price @ Call
Bernstein 17 Oct 2024 1,100.00 (24.46%) Buy 912.84
Truist Securities 10 Oct 2024 1,033.00 (16.88%) Buy 910.69
Deutsche Bank 03 Oct 2024 1,025.00 (15.98%) Buy 885.55
12 Aug 2024 1,025.00 (15.98%) Buy 884.38
Cantor Fitzgerald 16 Sep 2024 885.00 (0.14%) Buy 923.54
09 Sep 2024 885.00 (0.14%) Buy 908.27
Citigroup 13 Sep 2024 1,060.00 (19.94%) Buy 923.71
JP Morgan 13 Sep 2024 1,100.00 (24.46%) Buy 923.71
Morgan Stanley 27 Aug 2024 1,106.00 (25.14%) Buy 954.48
Guggenheim 16 Aug 2024 1,030.00 (16.54%) Buy 922.12
Berenberg 14 Aug 2024 1,050.00 (18.81%) Buy 931.68
B of A Securities 09 Aug 2024 1,125.00 (27.29%) Buy 891.68
BMO Capital 09 Aug 2024 1,101.00 (24.58%) Buy 891.68
Wells Fargo 09 Aug 2024 1,000.00 (13.15%) Buy 891.68
Show more

No data within this time range.

  • 3M
Date Type Details
16 Oct 2024 Announcement Survey reveals 8 in 10 Americans with ulcerative colitis struggle to find a public restroom during emergencies
16 Oct 2024 Announcement Lilly confirms date and conference call for third-quarter 2024 financial results announcement
14 Oct 2024 Announcement Lilly reports one-year histologic outcomes in Phase 3 study of mirikizumab compared to ustekinumab for Crohn's disease
02 Oct 2024 CNBC Eli Lilly to build $4.5 billion research and manufacturing center to propel drug pipeline
02 Oct 2024 Announcement Lilly announces new $4.5 billion site - the Lilly Medicine Foundry - to drive innovation in drug production and make medicines for clinical trials
25 Sep 2024 CNBC Novo Nordisk's diabetes drug Ozempic may lower the risk of opioid overdoses, study says
25 Sep 2024 Announcement New data show Lilly's EBGLYSS™ (lebrikizumab-lbkz) provided sustained disease control for up to three years in more than 80% of adults and adolescents with moderate-to-severe atopic dermatitis
24 Sep 2024 Announcement Lilly's Kisunla™ (donanemab-azbt) Approved in Japan for the Treatment of Early Symptomatic Alzheimer's Disease
24 Sep 2024 CNBC 'Stop ripping us off': Senate grills Novo Nordisk CEO on weight loss drug pricing
21 Sep 2024 CNBC FTC sues drug middlemen for allegedly inflating insulin prices
16 Sep 2024 CNBC Drugmakers bet billions that targeted radiation could become the next cancer breakthrough
13 Sep 2024 Announcement FDA Approves Lilly's EBGLYSS™ (lebrikizumab-lbkz) for Adults and Children 12 Years and Older with Moderate-to-Severe Atopic Dermatitis
12 Sep 2024 Announcement Lilly expands manufacturing footprint in Ireland with $1.8 billion investment
10 Sep 2024 Announcement With once-a-week dosing, insulin efsitora alfa delivers similar A1C reduction compared to daily insulin in adults with type 1 diabetes
10 Sep 2024 Announcement Once-weekly dose of insulin efsitora alfa delivers A1C reduction consistent with the most advanced daily insulin in people with type 2 diabetes
09 Sep 2024 Announcement Lilly appoints Lucas Montarce as executive vice president and chief financial officer
05 Sep 2024 Announcement In a first-of-its-kind fixed dose study, once weekly insulin efsitora alfa leads to A1C reduction similar to daily insulin
05 Sep 2024 TheFinance 3 US Blue-Chip Earnings Reports That You Should Not Miss
04 Sep 2024 Announcement Lilly and EVA Pharma collaborate to expand access to baricitinib in low- to middle-income countries
27 Aug 2024 Announcement Lilly releases Zepbound® (tirzepatide) single-dose vials, expanding supply and access for adults living with obesity
27 Aug 2024 CNBC Eli Lilly releases new form of weight loss drug Zepbound for half the price to boost access, supply
22 Aug 2024 Announcement Lilly to participate in Morgan Stanley 22nd Annual Global Healthcare Conference
20 Aug 2024 Announcement Tirzepatide reduced the risk of developing type 2 diabetes by 94% in adults with pre-diabetes and obesity or overweight
20 Aug 2024 CNBC Eli Lilly's weight loss drug slashes the risk of developing diabetes in long-term trial
16 Aug 2024 Announcement Lilly announces retirement of Marschall S. Runge from its Board of Directors
16 Aug 2024 Announcement Lilly Completes Acquisition of Morphic to Improve Outcomes and Expand Options for People Living with Inflammatory Bowel Disease
15 Aug 2024 CNBC Biden administration releases prices of 10 drugs in Medicare negotiations, says U.S. will save $6 billion in first year
13 Aug 2024 CNBC Digital health company Ro launches GLP-1 insurance-coverage checker to help patients navigate costs
13 Aug 2024 Announcement Lilly opens state-of-the-art research and development center in the Boston Seaport
08 Aug 2024 CNBC Eli Lilly blows past estimates, hikes guidance as Zepbound, Mounjaro sales soar
08 Aug 2024 Announcement Lilly Reports Q2 2024 Financial Results, Raises Full-Year Revenue Guidance by $3 Billion
03 Aug 2024 TheFinance Smart Look At The Week Ahead: DBS, Burger King, KFC, Jollibee, Haw Par, and SGX
03 Aug 2024 TheFinance Why Do Some Businesses Thrive? The Secret to Building Lasting Competitive Advantages
02 Aug 2024 CNBC Eli Lilly's Zepbound and Mounjaro now available in U.S. after shortages, FDA says
01 Aug 2024 Announcement Lilly's tirzepatide successful in phase 3 study showing benefit in adults with heart failure with preserved ejection fraction and obesity
01 Aug 2024 CNBC Eli Lilly's weight loss drug Zepbound cuts heart failure risks in late-stage study
30 Jul 2024 CNBC Older GLP-1 drug from Novo Nordisk may slow Alzheimer's disease progression by protecting the brain, study says
25 Jul 2024 Announcement Lilly Confirms Date and Conference Call for Second-Quarter 2024 Financial Results Announcement
25 Jul 2024 CNBC Viking Therapeutics stock jumps nearly 30% after drugmaker moves weight loss injection to late-stage trial
Show more
TTM Dividend Yield 0.57%
5Y Average Dividend Yield 1.36%
Payout Ratio 59.85%
Expected Next Dividend Payment Mar 2025
Ex Date Announcement Date Payment Date Details
15 Aug 2024 24 Jun 2024 10 Sep 2024 1.3 Cash
15 May 2024 06 May 2024 10 Jun 2024 1.3 Cash
14 Feb 2024 08 Dec 2023 08 Mar 2024 1.3 Cash
14 Nov 2023 01 Nov 2023 08 Dec 2023 1.13 Cash
14 Aug 2023 26 Jun 2023 08 Sep 2023 1.13 Cash
12 May 2023 01 May 2023 09 Jun 2023 1.13 Cash
14 Feb 2023 12 Dec 2022 10 Mar 2023 1.13 Cash
14 Nov 2022 17 Oct 2022 09 Dec 2022 0.98 Cash
12 Aug 2022 27 Jun 2022 09 Sep 2022 0.98 Cash
13 May 2022 02 May 2022 10 Jun 2022 0.98 Cash
14 Feb 2022 13 Dec 2021 10 Mar 2022 0.98 Cash
12 Nov 2021 18 Oct 2021 10 Dec 2021 0.85 Cash
12 Aug 2021 29 Jun 2021 10 Sep 2021 0.85 Cash
13 May 2021 03 May 2021 10 Jun 2021 0.85 Cash
11 Feb 2021 14 Dec 2020 10 Mar 2021 0.85 Cash
12 Nov 2020 19 Oct 2020 10 Dec 2020 0.74 Cash
13 Aug 2020 15 Jul 2020 10 Sep 2020 0.74 Cash
14 May 2020 04 May 2020 10 Jun 2020 0.74 Cash
13 Feb 2020 16 Dec 2019 10 Mar 2020 0.74 Cash
14 Nov 2019 22 Oct 2019 10 Dec 2019 0.645 Cash
14 Aug 2019 20 Jun 2019 10 Sep 2019 0.645 Cash
16 May 2019 07 May 2019 10 Jun 2019 0.645 Cash
14 Feb 2019 19 Dec 2018 08 Mar 2019 0.645 Cash
14 Nov 2018 16 Oct 2018 10 Dec 2018 0.5625 Cash
14 Aug 2018 19 Jun 2018 10 Sep 2018 0.5625 Cash
16 May 2018 07 May 2018 08 Jun 2018 0.5625 Cash
14 Feb 2018 11 Dec 2017 09 Mar 2018 0.5625 Cash
14 Nov 2017 16 Oct 2017 08 Dec 2017 0.52 Cash
11 Aug 2017 19 Jun 2017 08 Sep 2017 0.52 Cash
11 May 2017 01 May 2017 09 Jun 2017 0.52 Cash
13 Feb 2017 12 Dec 2016 10 Mar 2017 0.52 Cash
10 Nov 2016 17 Oct 2016 09 Dec 2016 0.51 Cash
11 Aug 2016 20 Jun 2016 09 Sep 2016 0.51 Cash
11 May 2016 02 May 2016 10 Jun 2016 0.51 Cash
10 Feb 2016 08 Dec 2015 10 Mar 2016 0.51 Cash
10 Nov 2015 19 Oct 2015 10 Dec 2015 0.5 Cash
12 Aug 2015 15 Jun 2015 10 Sep 2015 0.5 Cash
14 May 2015 04 May 2015 10 Jun 2015 0.5 Cash
11 Feb 2015 15 Dec 2014 10 Mar 2015 0.5 Cash
12 Nov 2014 20 Oct 2014 10 Dec 2014 0.49 Cash
13 Aug 2014 16 Jun 2014 10 Sep 2014 0.49 Cash
13 May 2014 05 May 2014 10 Jun 2014 0.49 Cash
12 Feb 2014 16 Dec 2013 10 Mar 2014 0.49 Cash
13 Nov 2013 21 Oct 2013 10 Dec 2013 0.49 Cash
13 Aug 2013 18 Jun 2013 10 Sep 2013 0.49 Cash
14 May 2013 03 May 2013 10 Jun 2013 0.49 Cash
13 Feb 2013 17 Dec 2012 08 Mar 2013 0.49 Cash
13 Nov 2012 15 Oct 2012 10 Dec 2012 0.49 Cash
13 Aug 2012 19 Jun 2012 10 Sep 2012 0.49 Cash
13 Feb 2012 12 Dec 2011 09 Mar 2012 0.49 Cash
10 Nov 2011 17 Oct 2011 09 Dec 2011 0.49 Cash
11 Aug 2011 20 Jun 2011 09 Sep 2011 0.49 Cash
11 May 2011 18 Apr 2011 10 Jun 2011 0.49 Cash
11 Feb 2011 13 Dec 2010 10 Mar 2011 0.49 Cash
10 Nov 2010 18 Oct 2010 10 Dec 2010 0.49 Cash
11 Aug 2010 21 Jun 2010 10 Sep 2010 0.49 Cash
12 May 2010 19 Apr 2010 10 Jun 2010 0.49 Cash
10 Feb 2010 14 Dec 2009 10 Mar 2010 0.49 Cash
10 Nov 2009 19 Oct 2009 10 Dec 2009 0.49 Cash
12 Aug 2009 22 Jun 2009 10 Sep 2009 0.49 Cash
13 May 2009 20 Apr 2009 10 Jun 2009 0.49 Cash
11 Feb 2009 15 Dec 2008 10 Mar 2009 0.49 Cash
12 Nov 2008 20 Oct 2008 10 Dec 2008 0.47 Cash
13 Aug 2008 20 Jun 2008 10 Sep 2008 0.47 Cash
13 Feb 2008 17 Dec 2007 10 Mar 2008 0.47 Cash
13 Nov 2007 15 Oct 2007 10 Dec 2007 0.425 Cash
13 Aug 2007 21 Jun 2007 10 Sep 2007 0.425 Cash
11 May 2007 16 Apr 2007 08 Jun 2007 0.425 Cash
13 Feb 2007 18 Dec 2006 09 Mar 2007 0.425 Cash
13 Nov 2006 16 Oct 2006 08 Dec 2006 0.4 Cash
11 Aug 2006 26 Jun 2006 08 Sep 2006 0.4 Cash
11 May 2006 24 Apr 2006 09 Jun 2006 0.4 Cash
13 Feb 2006 19 Dec 2005 10 Mar 2006 0.4 Cash
10 Nov 2005 17 Oct 2005 09 Dec 2005 0.38 Cash
11 Aug 2005 24 Jun 2005 09 Sep 2005 0.38 Cash
11 May 2005 18 Apr 2005 10 Jun 2005 0.38 Cash
11 Feb 2005 20 Dec 2004 10 Mar 2005 0.38 Cash
10 Nov 2004 18 Oct 2004 10 Dec 2004 0.355 Cash
11 Aug 2004 28 Jun 2004 10 Sep 2004 0.355 Cash
12 May 2004 19 Apr 2004 10 Jun 2004 0.355 Cash
11 Feb 2004 15 Dec 2003 10 Mar 2004 0.355 Cash
12 Nov 2003 20 Oct 2003 10 Dec 2003 0.335 Cash
13 Aug 2003 23 Jun 2003 10 Sep 2003 0.335 Cash
13 May 2003 28 Apr 2003 10 Jun 2003 0.335 Cash
12 Feb 2003 16 Dec 2002 10 Mar 2003 0.335 Cash
13 Nov 2002 21 Oct 2002 10 Dec 2002 0.31 Cash
13 Aug 2002 24 Jun 2002 10 Sep 2002 0.31 Cash
13 May 2002 15 Apr 2002 10 Jun 2002 0.31 Cash
13 Feb 2002 17 Dec 2001 08 Mar 2002 0.31 Cash
13 Nov 2001 15 Oct 2001 10 Dec 2001 0.28 Cash
13 Aug 2001 25 Jun 2001 10 Sep 2001 0.28 Cash
11 May 2001 16 Apr 2001 11 Jun 2001 0.28 Cash
13 Feb 2001 18 Dec 2000 09 Mar 2001 0.28 Cash
13 Nov 2000 16 Oct 2000 11 Dec 2000 0.26 Cash
11 Aug 2000 26 Jun 2000 11 Sep 2000 0.26 Cash
11 May 2000 17 Apr 2000 09 Jun 2000 0.26 Cash
11 Feb 2000 20 Dec 1999 10 Mar 2000 0.26 Cash
10 Nov 1999 18 Oct 1999 10 Dec 1999 0.23 Cash
11 Aug 1999 19 Jul 1999 10 Sep 1999 0.23 Cash
12 May 1999 19 Apr 1999 10 Jun 1999 0.23 Cash
10 Feb 1999 21 Dec 1998 10 Mar 1999 0.23 Cash
10 Nov 1998 20 Oct 1998 10 Dec 1998 0.2 Cash
12 Aug 1998 20 Jul 1998 10 Sep 1998 0.2 Cash
13 May 1998 20 Apr 1998 10 Jun 1998 0.2 Cash
11 Feb 1998 15 Dec 1997 10 Mar 1998 0.2 Cash
12 Nov 1997 15 Sep 1997 10 Dec 1997 0.2 Cash
13 Aug 1997 21 Jul 1997 10 Sep 1997 0.36 Cash
13 May 1997 21 Apr 1997 10 Jun 1997 0.36 Cash
12 Feb 1997 16 Dec 1996 10 Mar 1997 0.36 Cash
13 Nov 1996 21 Oct 1996 10 Dec 1996 0.3425 Cash
13 Aug 1996 15 Jul 1996 10 Sep 1996 0.3425 Cash
13 May 1996 15 Apr 1996 10 Jun 1996 0.3425 Cash
13 Feb 1996 18 Dec 1995 11 Mar 1996 0.3425 Cash
13 Nov 1995 17 Oct 1995 11 Dec 1995 0.685 Cash
11 Aug 1995 17 Jul 1995 11 Sep 1995 0.645 Cash
09 May 1995 17 Apr 1995 12 Jun 1995 0.645 Cash
Show more

Annual Dividend Yield

Year Annual Dividend ($) Frequency/Year Yield %
2024 3.90 3 0.44
2023 4.52 4 0.78
2022 3.92 4 1.07
2021 3.40 4 1.23
2020 2.96 4 1.75
2019 2.58 4 1.96
2018 2.25 4 1.94
2017 2.08 4 2.46
2016 2.04 4 2.77
2015 2.00 4 2.37
2014 1.96 4 2.84
2013 1.96 4 3.84
2012 1.47 3 2.98
2011 1.96 4 4.72
2010 1.96 4 5.59
2009 1.96 4 5.49
2008 1.41 3 3.50
2007 1.70 4 3.18
2006 1.60 4 3.07
2005 1.52 4 2.69
2004 1.42 4 2.50
2003 1.34 4 1.91
2002 1.24 4 1.95
2001 1.12 4 1.43
2000 1.04 4 1.12
1999 0.920 4 1.38
1998 0.800 4 0.90
1997 1.28 4 1.84
1996 1.37 4 3.75
1995 1.98 3 7.02
Show more

The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.

Portfolio

Template

Your price alert

Risk Profile

| | | | |
Conservative
Moderate Conservative
Moderate
Moderate Aggressive
Aggressive
Margin of Safety (EP)
Partial Profit (TP1)
Target Profit (TP2)
Maximum Loss (SL)

Disclaimer: The above is for illustrative purposes only and is NOT investment advice. Seek advice from a qualified financial professional.

Entry Price (EP)

Take Profit 1 (TP1)

Take Profit 2 (TP2)

Stop Loss (SL)

52W Range
 
52WL
 
52WH
SL
EP
TP1
TP2

All alert prices are within 52 weeks price range

Realized Profit -
Unrealized Profit -
Dividend Received 2024 -
Total Profit -
Avg. Return -
Quantity (Buy) -
Avg. Price (Buy) -
Quantity (Sold) -
Avg. Price (Sold) -
No stocks matching your criteria